# A Phase II Clinical Trial Evaluating the Efficacy and Safety of SYS6026 Injection in Participants With HPV16 or 18-related High-grade Cervical Squamous Intraepithelial Lesions

> **NCT07702656** · PHASE2 · NOT_YET_RECRUITING · sponsor: **CSPC Megalith Biopharmaceutical Co.,Ltd.** · enrollment: 175 (estimated)

## Conditions studied

- High-grade Cervical Intraepithelial Lesions

## Interventions

- **BIOLOGICAL:** SYS6026
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT07702656
- **Lead sponsor:** CSPC Megalith Biopharmaceutical Co.,Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-10
- **Primary completion:** 2028-09-30
- **Final completion:** 2028-12-30
- **Target enrollment:** 175 (ESTIMATED)
- **Last updated:** 2026-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07702656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07702656, "A Phase II Clinical Trial Evaluating the Efficacy and Safety of SYS6026 Injection in Participants With HPV16 or 18-related High-grade Cervical Squamous Intraepithelial Lesions". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07702656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*